Evidence map›Paper›PMID 28946883›Full record

ArticleMalaria journal2017

IgG antibodies to synthetic GPI are biomarkers of immune-status to both Plasmodium falciparum and Plasmodium vivax malaria in young children.

Camila T França, Connie S N Li Wai Suen, Amandine Carmagnac, Enmoore Lin, Benson Kiniboro, Peter Siba, Louis Schofield, Ivo Mueller

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Unveiling the Sugary Secrets ofFrontiers in microbiology · 2021
    Review
  4. Antibody Profiles toThe American journal of tropical medicine and hygiene · 2020
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 4 countries.

Camila T FrançaPopulation Health and Immunity Division, Walter and Eliza Hall Institute, Parkville, VIC, Australia. franca.c@wehi.edu.au.
Connie S N Li Wai SuenPopulation Health and Immunity Division, Walter and Eliza Hall Institute, Parkville, VIC, Australia.
Amandine CarmagnacInfection and Immunity Division, Walter and Eliza Hall Institute, Parkville, VIC, Australia.
Enmoore LinMalaria Immuno-Epidemiology Unit, PNG Institute of Medical Research, Madang, Madang Province, Papua New Guinea.
Benson KiniboroMalaria Immuno-Epidemiology Unit, PNG Institute of Medical Research, Madang, Madang Province, Papua New Guinea.
Peter SibaMalaria Immuno-Epidemiology Unit, PNG Institute of Medical Research, Madang, Madang Province, Papua New Guinea.
Louis SchofieldPopulation Health and Immunity Division, Walter and Eliza Hall Institute, Parkville, VIC, Australia.
Ivo MuellerPopulation Health and Immunity Division, Walter and Eliza Hall Institute, Parkville, VIC, Australia.
Walter and Eliza Hall Institute of Medical Research · AUPapua New Guinea Institute of Medical Research · PGUniversity of Melbourne · AU

Funding

TransmissionU19AI089686 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI KAZURA, JAMES WALTER · 2010 to 2016
$9.9M
The effect of mixed Plasmodium infections on morbidityR03AI063135 · NIAID · PAPUA NEW GUINEA INST/ MEDICAL RESEARCH · PI MUELLER, IVO · 2005 to 2006
$103k
NIAID NIH HHS R03 AI063135NIAID NIH HHS U19 AI089686
6 · The paper itself

Abstract

backgroundFurther reduction in malaria prevalence and its eventual elimination would be greatly facilitated by the development of biomarkers of exposure and/or acquired immunity to malaria, as well as the deployment of effective vaccines against Plasmodium falciparum and Plasmodium vivax. A better understanding of the acquisition of immunity in naturally-exposed populations is essential for the identification of antigens useful as biomarkers, as well as to inform rational vaccine development.

methodsELISA was used to measure total IgG to a synthetic form of glycosylphosphatidylinositol from P. falciparum (PfGPI) in a cohort of 1-3 years old Papua New Guinea children with well-characterized individual differences in exposure to P. falciparum and P. vivax blood-stage infections. The relationship between IgG levels to PfGPI and measures of recent and past exposure to P. falciparum and P. vivax infections was investigated, as well as the association between antibody levels and prospective risk of clinical malaria over 16 months of follow-up.

resultsTotal IgG levels to PfGPI were low in the young children tested. Antibody levels were higher in the presence of P. falciparum or P. vivax infections, but short-lived. High IgG levels were associated with higher risk of P. falciparum malaria (IRR 1.33-1.66, P = 0.008-0.027), suggesting that they are biomarkers of increased exposure to P. falciparum infections. Given the cross-reactive nature of antibodies to PfGPI, high IgG levels were also associated with reduced risk of P. vivax malaria (IRR 0.65-0.67, P = 0.039-0.044), indicating that these antibodies are also markers of acquired immunity to P. vivax.

conclusionsThis study highlights that in young children, IgG to PfGPI might be a useful marker of immune-status to both P. falciparum and P. vivax infections, and potentially useful to help malaria control programs to identify populations at-risk. Further functional studies are necessary to confirm the potential of PfGPI as a target for vaccine development.

Indexed as

Adaptive ImmunityAntibodies, ProtozoanBiomarkersGlycosylphosphatidylinositolsHumansImmunoglobulin GInfantInfant, NewbornLongitudinal StudiesMalaria, FalciparumMalaria, VivaxPapua New GuineaPlasmodium falciparumPlasmodium vivaxPolysaccharidesAntibodies, ProtozoanBiomarkersGlycosylphosphatidylinositolsImmunoglobulin GPolysaccharidesBiomarker of exposureClinical malariaExposureGlycosylphosphatidylinositolGPIIgG antibodyMalaria eliminationPlasmodium falciparumPlasmodium vivaxProtection

Identifiers

PMID28946883
PMCPMC5613389
OpenAlexW2759389603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.